Nationwide McDonald's Boycott This Week: Latest Update From Organizer
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
The organization behind a nationwide boycott of McDonald's that is set to start on Tuesday said the movement is "about more than burgers and fries."
As part of its ongoing "Economic Blackout Tour," The People's Union USA, the movement behind recent boycotts of Target and Walmart, is urging Americans to refrain from eating at the fast-food chain between June 24 and June 30.
"This is about power," the organization said in a post shared by its founder John Schwarz on Instagram on Saturday. "When we unite and hit corporations in their wallets, they listen."
Newsweek has reached out to McDonald's via email for comment.
Why It Matters
The first half of 2025 has been marked by boycotts of several household-name companies, sparked by certain corporations rolling back diversity, equity and inclusion (DEI) initiatives, as well as wider pushback against practices such as tax avoidance and underpaying workers.
Since late 2023, McDonald's has also been battling a boycott led by the pro-Palestinian Boycott, Divestment, Sanctions (BDS) movement for alleged complicity with the actions of the Israeli military in the Gaza Strip.
What To Know
The People's Union USA describes itself on its website as "a grassroots movement focused on economic resistance, corporate accountability, and real justice for the working class."
Since February, the group has orchestrated boycotts of Amazon, Walmart and Target, as well as periodic "economic blackouts," during which it says Americans should "avoid shopping, streaming, online orders, fast food, and everything in between," and rely exclusively on small, local businesses.
The movement said it is demanding "fair taxes, an end to price gouging, real equality, and corporate accountability" through its upcoming boycott of McDonald's.
Last week, The People's Union USA accused McDonald's in an Instagram post of engaging in "performative DEI with no meaningful change." The movement also alleged that the company pays its workers low wages and suppresses workers' rights and union efforts.
An exterior view of the McDonald's restaurant at the Lycoming Mall.
An exterior view of the McDonald's restaurant at the Lycoming Mall.
Alamy Live News via AP
What People Are Saying
The People's Union USA in an Instagram post shared by founder John Schwarz: "This is a show of strength, solidarity, and people powered change. Let them feel it. Let them hear us. Let this be just the beginning."
Chris Kempczinski, chairman and CEO of McDonald's Corporation, in a January 2024 LinkedIn post: "I also recognize that several markets in the Middle East and some outside the region are experiencing a meaningful business impact due to the war and associated misinformation that is affecting brands like McDonald's. This is disheartening and ill-founded."
Genna Gent, vice president of government relations for McDonald's, in a 2019 letter to the National Restaurant Association and obtained by Politico: "Going forward, McDonald's Corporation will not use our resources, including lobbyists or staff, to oppose minimum wage increases at the federal, state or local levels. Nor will we participate in the association advocacy efforts designed expressly to defeat wage increases."
What Happens Next?
The People's Union USA said it is planning an economic blackout for July 4, along with boycotts of Starbucks, Amazon and Home Depot throughout the month.
During the month of August, the movement is planning boycotts of Walmart, McDonald's and Lowe's.
Do you have a story that Newsweek should be covering? Do you have any questions about this story? Contact LiveNews@newsweek.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Boston Globe
16 minutes ago
- Boston Globe
‘I'm going to keep on fighting.' AG Campbell testifies before Dems in Congress about fighting the Trump administration in court
'Americans have no greater ally than their state attorneys general,' said Durbin. 'They're engaged in multi-pronged efforts to protect the Constitution, the public interest, and to hold the federal government to account.' Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up Raskin, a former Constitutional law professor, quoted multiple sections of the nation's Advertisement 'The framers [of the Constitution], the founders, were most seriously afraid of a president who would act like a mad king drunk on power,' Raskin said. Since Trump's first days in office, Democratic state attorneys general have vowed to push back in court against what they characterize as the president overstepping his bounds. In the ensuing months, those attorneys general have created a working coalition, often filing litigation together challenging Trump administration actions ranging from federal funding cuts to deportations to bans on diversity, equity, and inclusion initiatives. Federal judges appointed by both Democratic Advertisement Campbell, along with the attorney generals of Minnesota, Illinois, and New Jersey — all of whom also appeared before the panel of Democratic lawmakers — have been at the forefront of anti-Trump litigation. Many of the successful suits against the White House have played out in federal 'As state AGs, we've been punching above our weight and playing a vital role in this moment. I often say Massachusetts is small, but I feel like Muhammad Ali in this moment, I'm going to keep on fighting,' Campbell said. 'We are fighting for our democracy, our Constitution, a system of checks and balances, the rule of law, and our children, and the next generation to come.' A majority of the questions from lawmakers revolved around the legality of tactics Immigration and Customs Enforcement has used amidst the Trump administration's wide ranging effort to deport undocumented immigrants. Additionally, they raised concerns around racial profiling in immigration arrests, ICE agents masking their faces, and a breakdown of communication between local and federal law enforcement. Campbell, expressed concern about the violation of due process rights of individuals arrested by ICE, and highlighted the stories of Tufts doctoral student since been released from custody. Advertisement Those arrests 'create fear in our communities,' she said. 'We are doing everything in our power, collectively, to hold the administration accountable, not just through our litigation efforts to protect due process, but also putting out guidance... But I do hope folks continue to mobilize in the streets. It makes a difference.' Multiple times over the course of the three hour forum, members of Congress singled out Campbell for praise on her work leading a suit against cuts to National Institutes of Health funding, which resulted in a permanent injunction against the cuts. After the hearing concluded, Campbell told the Globe she was 'grateful' for questions about that case. 'It lifts up the leadership of Massachusetts and our standing when it comes to biomedical research, our healthcare institutions, which are internationally renowned, along with our higher ed institutions,' she said. 'At the same time, the devastating effect that these NIH cuts have, not just on Massachusetts, but the country as a whole and our international standing.' But, Campbell said, labeling the NIH funding decision a complete victory doesn't tell the whole story because, despite the favorable ruling, 'people are still losing their jobs, a clinical trial for someone who has pediatric cancer has still been canceled, folks are still losing resources.' Julian E.J. Sorapuru can be reached at
Business Wire
19 minutes ago
- Business Wire
ZEISS Vision Care US Names Healthcare Industry Veteran Gary Rosenblum as President and Chief Executive Officer
HEBRON, Ky.--(BUSINESS WIRE)-- ZEISS Vision Care, one of the world's leading manufacturers of eyeglass lenses and ophthalmic instruments, announced today that Gary Rosenblum has been named President and Chief Executive Officer of ZEISS Vision Care US, effective June 16, 2025. Rosenblum brings relevant senior leadership experience at Demant, Johnson & Johnson, Abbott and Pfizer to his new role. He succeeds Jens Boy, who has spent more than a decade driving the ZEISS Vision Care business in North America, and will depart the company in pursuit of new opportunities on June 30, 2025. Rosenblum joins ZEISS following more than eight years at Oticon, a division of Demant, where he served as President for US Hearing Aids and led efforts to bring the company's life-changing hearing solutions to Americans with mild-to-severe hearing loss. Under his leadership, Oticon achieved outstanding results in terms of growing market share and increasing revenue, driven by new approaches in sales, talent development and transformation. Before that, Rosenblum led the Enterprise Customer Team at Johnson & Johnson, working with the largest hospital systems on the West Coast. He's also served as Director, Global Strategic Marketing at Abbott, leading the charge in the worldwide commercialization of the company's Diabetes Care portfolio. 'Gary's hands-on experience in highly relevant healthcare roles and his proven track record of success make him an excellent fit to join the ZEISS Vision Care team,' said Sven Hermann, CEO ZEISS Consumer Markets. 'With Gary at the helm, I am confident we will continue our positive momentum and maintain ZEISS' leadership in the US market. I am incredibly grateful for the role Jens played in transforming ZEISS Vision Care in North America over the past ten years and wish him the best in his future endeavors.' In his role as president and CEO, Rosenblum will focus on growing ZEISS Vision Care US, both in terms of the core business and future opportunities. Driven by a commitment to protect and improve eye health, he is passionate about continuing the legacy of innovation that has guided ZEISS for more than 179 years. 'I am thrilled to join ZEISS Vision Care and continue to build on the company's mission of delivering industry-leading optical innovations to eyecare professionals and millions of Americans,' said Rosenblum. 'I am already impressed with our incredible team in the US and their commitment to excellence. I'd like to thank Jens for his support with this transition and look forward to continuing his record of success for the company.' About ZEISS ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous fiscal year, the ZEISS Group generated annual revenue totaling 10 billion euros in its four segments Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology and Consumer Markets (status: 30 September 2023). For its customers, ZEISS develops, produces and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars. With a portfolio aligned with future growth areas like digitalization, healthcare and Smart Production and a strong brand, ZEISS is shaping the future of technology and constantly advancing the world of optics and related fields with its solutions. The company's significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS' technology and market leadership. ZEISS invests 15 percent of its revenue in research and development – this high level of expenditure has a long tradition at ZEISS and is also an investment in the future. With over 43,000 employees, ZEISS is active globally in almost 50 countries with around 30 production sites, 60 sales and service companies and 27 research and development facilities (status: 30 September 2023). Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. The Carl Zeiss Foundation, one of the largest foundations in Germany committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG. ZEISS Vision Care is one of the world's leading manufacturers of eyeglass lenses and ophthalmic instruments. The unit is allocated to the Consumer Markets segment and develops and produces offerings for the entire eyeglass value chain that are distributed globally under the ZEISS brand.
Yahoo
20 minutes ago
- Yahoo
ZEISS Vision Care US Names Healthcare Industry Veteran Gary Rosenblum as President and Chief Executive Officer
Most Recently Serving as President for Oticon, a Division of Demant, Rosenblum Brings 30+ Years of Experience in Medical Technology and Consumer Healthcare to ZEISS HEBRON, Ky., June 23, 2025--(BUSINESS WIRE)--ZEISS Vision Care, one of the world's leading manufacturers of eyeglass lenses and ophthalmic instruments, announced today that Gary Rosenblum has been named President and Chief Executive Officer of ZEISS Vision Care US, effective June 16, 2025. Rosenblum brings relevant senior leadership experience at Demant, Johnson & Johnson, Abbott and Pfizer to his new role. He succeeds Jens Boy, who has spent more than a decade driving the ZEISS Vision Care business in North America, and will depart the company in pursuit of new opportunities on June 30, 2025. Rosenblum joins ZEISS following more than eight years at Oticon, a division of Demant, where he served as President for US Hearing Aids and led efforts to bring the company's life-changing hearing solutions to Americans with mild-to-severe hearing loss. Under his leadership, Oticon achieved outstanding results in terms of growing market share and increasing revenue, driven by new approaches in sales, talent development and transformation. Before that, Rosenblum led the Enterprise Customer Team at Johnson & Johnson, working with the largest hospital systems on the West Coast. He's also served as Director, Global Strategic Marketing at Abbott, leading the charge in the worldwide commercialization of the company's Diabetes Care portfolio. "Gary's hands-on experience in highly relevant healthcare roles and his proven track record of success make him an excellent fit to join the ZEISS Vision Care team," said Sven Hermann, CEO ZEISS Consumer Markets. "With Gary at the helm, I am confident we will continue our positive momentum and maintain ZEISS' leadership in the US market. I am incredibly grateful for the role Jens played in transforming ZEISS Vision Care in North America over the past ten years and wish him the best in his future endeavors." In his role as president and CEO, Rosenblum will focus on growing ZEISS Vision Care US, both in terms of the core business and future opportunities. Driven by a commitment to protect and improve eye health, he is passionate about continuing the legacy of innovation that has guided ZEISS for more than 179 years. "I am thrilled to join ZEISS Vision Care and continue to build on the company's mission of delivering industry-leading optical innovations to eyecare professionals and millions of Americans," said Rosenblum. "I am already impressed with our incredible team in the US and their commitment to excellence. I'd like to thank Jens for his support with this transition and look forward to continuing his record of success for the company." About ZEISS ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous fiscal year, the ZEISS Group generated annual revenue totaling 10 billion euros in its four segments Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology and Consumer Markets (status: 30 September 2023). For its customers, ZEISS develops, produces and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars. With a portfolio aligned with future growth areas like digitalization, healthcare and Smart Production and a strong brand, ZEISS is shaping the future of technology and constantly advancing the world of optics and related fields with its solutions. The company's significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS' technology and market leadership. ZEISS invests 15 percent of its revenue in research and development – this high level of expenditure has a long tradition at ZEISS and is also an investment in the future. With over 43,000 employees, ZEISS is active globally in almost 50 countries with around 30 production sites, 60 sales and service companies and 27 research and development facilities (status: 30 September 2023). Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. The Carl Zeiss Foundation, one of the largest foundations in Germany committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG. Further information at ZEISS Vision Care ZEISS Vision Care is one of the world's leading manufacturers of eyeglass lenses and ophthalmic instruments. The unit is allocated to the Consumer Markets segment and develops and produces offerings for the entire eyeglass value chain that are distributed globally under the ZEISS brand. View source version on Contacts Press contact Allison for ZEISS Vision CareRebecca BuddinghPhone: +1 619 207 8007E-Mail:
